NgoSeptemba 27, i-website esemthethweni ye-CDE ibonise ukuba isicelo sesalathiso esitsha sePfize Crisaborole cream (igama lezorhwebo laseTshayina: iSultanming, igama lezorhwebo lesiNgesi: Eucris a, Staquis) lamkelwa, mhlawumbi kubantwana kunye nabantu abadala abaneminyaka eyi-3 kunye abantu abadala atopic dermatitis.

I-Crisaborole yi-molecule encinci, i-non-hormonal, i-nonsteroidal anti-inflammatory topical phosphodiesterase 4 (PDE-4) inhibitor eyenziwe ngu-Anacor.NgoMeyi ka-2016, iPfizer yafumana inkampani nge-5.2 yeebhiliyoni zeedola kwaye yafumana ichiza.NgoDisemba waloo nyaka, iCrisaborole yamkelwa yi-FDA yokuthengisa, yaba lichiza lokuqala elimiselweyo kwi-atopic dermatitis evunyiweyo kwiminyaka eyi-10, kunye neyeza lokuqala le-nonsteroidal langaphandle lokuthintela ulusu lwe-PDE4.

I-Crisaborole Inhibitors njengeyeza elitsha, enyanisweni, iifom zedosi yomlomo zisetyenziselwe i-plaque psoriasis kunye ne-psoriatic arthritis, eyona mpembelelo iphambili kukungahambi kakuhle kwesisu, akukho linye ibala elikhethekileyo.

I-Crisaborole njengeziyobisi ze-Topical, ezifakwe ngaphantsi kwesikhumba, amathuba okuba le mpembelelo yecala lokukhathazeka kwesisu nawo ancitshiswe aphantsi kakhulu.

Ngenxa yoko, iCrisaborole ngequbuliso yaba "lithemba lelali yonke" ukusukela kwiminyaka eyi-15, oogqirha kunye nabazali bebenomdla wokufumana ukusetyenziswa okukhuselekileyo, okusebenzayo kunye nexesha elide kwamachiza e-topical kude kakhulu.

Lisebenza kangakanani ichiza kunye neCrisaborole?

Kwi-2016, izifundo ezimbini zeSigaba sesi-III sovavanyo lwezonyango zisa iindaba ezimnandi kakhulu, i-Crisaborole, i-ointment ye-topical ye-phosphodiesterase-4 (PDE4) inhibitors, kwizigulane ezine-atopic dermatitis ngaphezu kweminyaka eyi-2 ubudala (abantwana kunye nabantu abadala), bafumana iziphumo ezilungileyo zeklinikhi.